Show simple item record

dc.contributor.authorFineberg, Naomi
dc.contributor.authorGale, T.M.
dc.contributor.authorSivakumaran, T.
dc.date.accessioned2010-02-10T11:29:11Z
dc.date.available2010-02-10T11:29:11Z
dc.date.issued2006
dc.identifier.citationFineberg , N , Gale , T M & Sivakumaran , T 2006 , ' A review of antipsychotics in the treatment of obsessive compulsive disorder ' , Journal of Psychopharmacology , vol. 20 , no. 1 , pp. 97-103 . https://doi.org/10.1177/0269881105056640
dc.identifier.issn0269-8811
dc.identifier.otherPURE: 193064
dc.identifier.otherPURE UUID: 5036e7f2-4e6c-488a-ad4d-70ffcb360104
dc.identifier.otherdspace: 2299/4248
dc.identifier.otherScopus: 33645233540
dc.identifier.urihttp://hdl.handle.net/2299/4248
dc.descriptionOriginal article can be found at: http://jop.sagepub.com/ Copyright British Association for Psychopharmacology. DOI: 10.1177/0269881105056640 [Full text of this article is not available in the UHRA]
dc.description.abstractAlthough many individuals with obsessive compulsive disorder (OCD) show significant improvement after treatment with serotonin reuptake inhibitors (SRIs), the treatment effect is usually partial and residual symptoms remain in most cases despite continued treatment. The proportion of patients failing to achieve a satisfactory outcome is difficult to define, but may be estimated at approximately 40% of cases. Even after switching to a second SRI, approximately 30% of cases do not respond (March et al., 1997). While there is a wealth of empirical data supporting first-line treatment of OCD, the evidence–base for second-line treatments is slim. In this paper we review current evidence for co-administration of antipsychotics in SRI resistant cases of OCD, based upon, wherever possible, randomized controlled trials (RCTs). Uncontrolled studies are cited where systematic data are lacking (so far there have been no meta-analyses of treatment studies for this subgroup). A systematic search of electronic databases (EMBase [1974-date], MEDLINE [1966-date], PsychInfo [1987-date]) was run using combinations of the terms obsessive compulsive and (randomized or control or clinical trial or placebo or blind) or (systematic or review or meta-analysis), as well as individual drug names. This was complemented by consulting with colleagues in the field and reviewing recent unpublished data presented at international, peer-reviewed symposia. Most published studies have investigated acute treatment of OCD, with a shortage of data relating to the treatment-resistant condition. Previous reviews of this area (e.g., Sareen et al., 2004) have been superceded by the publication of several new studies within the last 12 months.en
dc.language.isoeng
dc.relation.ispartofJournal of Psychopharmacology
dc.titleA review of antipsychotics in the treatment of obsessive compulsive disorderen
dc.contributor.institutionDepartment of Psychology
dc.contributor.institutionCentre for Health Services and Clinical Research
dc.contributor.institutionDepartment of Psychology and Sports Sciences
dc.contributor.institutionSchool of Life and Medical Sciences
dc.description.statusPeer reviewed
rioxxterms.versionofrecordhttps://doi.org/10.1177/0269881105056640
rioxxterms.typeJournal Article/Review
herts.preservation.rarelyaccessedtrue


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record